Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pulmonary Arterial Hypertension: full-pipeline trial registry
21 of 64 indexed Pulmonary Arterial Hypertension trials are currently recruiting.
Corpus placement: #215 of 28,707 conditions by registered trial count.
64 US clinical trials · 21 currently recruiting · #215 of 28,707 conditions by registered trial count
Pulmonary Arterial Hypertension: 64 US clinical trials tracked, 21 recruiting.
Pulmonary Arterial Hypertension is the subject of 64 registered US clinical trials on ClinicalTrials.gov, 21 of them currently open to new participants. 18 are in Phase 3-4 (later-stage) and 22 in Phase 1-2 (earlier-stage). The most active sponsor is Actelion, running 7 of these trials.
Enrollment posture brief
Registry condition pulmonary-arterial-hypertension
OPEN 21 | RECR 33% | LATE 18 | EARLY 22 | RANK #215 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Diabetes Mellitus, Type 1 (33% recruiting · 119 trials)
Pulmonary Arterial Hypertension lists 21 open slots (33% of 64 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pulmonary Arterial Hypertension on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pulmonary Arterial Hypertension is recruiting below its size-band peers.
21 of 64 indexed trials (32.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Pulmonary Arterial Hypertension trials is spread across many organizations.
Actelion accounts for 7 of 64 trials (10.9%). 41 distinct sponsors appear on at least one study for this condition label.
-
Most Pulmonary Arterial Hypertension trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 64 trials that report a genuine target (sentinel values excluded). 45 of those (70.3%) plan for fewer than 100 participants.
-
Pulmonary Arterial Hypertension research is mostly interventional.
51 interventional and 13 observational studies make up this index (79.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
64 total, page 2 of 2
Right Ventricular Metabolism in Pulmonary Arterial Hypertension
Vanderbilt University Medical Center
NCT02763735
Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension
University of Alabama at Birmingham
NCT01330108
Subcutaneous Elafin in Healthy Subjects
Roham T. Zamanian
NCT03522935
Effects of DHEA in Pulmonary Hypertension
Rhode Island Hospital
NCT03648385
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
Johns Hopkins University
NCT01042158
Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension
University of Cincinnati
NCT00403650
Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension
Actelion
NCT03187678
Anastrozole in Patients With Pulmonary Arterial Hypertension
University of Pennsylvania
NCT01545336
Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)
University of Chicago
NCT00452218
A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension
University of Chicago
NCT01757808
Nitric Oxide, GeNO Nitrosyl Delivery System
Wake Forest University Health Sciences
NCT01165047
Oral Iron Supplementation in Pulmonary Hypertension
The Cleveland Clinic
NCT01446848
Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
NCT01268553
Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401
Actelion
NCT01105117
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 16 |
| Phase 3 | 7 |
| Phase 4 | 11 |
Top Sponsors
Named interventions
Most-linked intervention names on Pulmonary Arterial Hypertension records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pulmonary Arterial Hypertension trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pulmonary Arterial Hypertension page
64 registered trials, 21 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 21 Pulmonary Arterial Hypertension trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Actelion sponsors the most Pulmonary Arterial Hypertension trials on record, review their full trial history before evaluating a specific study. See Actelion's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pulmonary Arterial Hypertension condition card totals 64 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.